NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.
1 .- 35 . (canceled)
36 . A pharmaceutical composition of an anticonvulsant agent comprising solid particles of the agent coated with one or more surface modifiers, wherein the particles have an average effective particle size of less than about 50 nm to less than about 1000 nm.
37 . The composition of claim 36 , wherein the surface modifier is selected from the group consisting of: anionic surfactants, cationic surfactants, zwitterionic surfactants, nonionic surfactants, surface active biological modifiers, and combinations thereof.
38 . The composition of claim 37 , wherein the anionic surfactant is selected from the group consisting of: alkyl sulfonates, alkyl phosphates, triethanolamine stearate, sodium lauryl sulfate, sodium dodecylsulfate, alkyl polyoxyethylene sulfates, sodium alginate, dioctyl sodium sulfosuccinate, sodium carboxymethylcellulose, and calcium carboxymethylcellulose.
39 . The composition of claim 37 , wherein the cationic surfactant is selected from the group consisting of quaternary ammonium compounds, benzalkonium chloride, dimethylaminoethanecarbamoyl cholesterol, alkyl pyridinium halides, n-octylamine and oleylamine.
40 . The composition of claim 37 , wherein the anionic surfactant is a natural or synthetic phospholipid.
41 . The composition of claim 37 , wherein the cationic surfactant is a natural or synthetic phospholipid.
42 . The composition of claim 37 , wherein the zwitterionic surfactant is a phospholipid, and wherein the phospholipid is natural or synthetic.
43 . The composition of claim 37 , wherein the nonionic surfactant is selected from the group consisting of: polyoxyethylene fatty alcohol ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan esters, glycerol monostearate, polyethylene glycols, polypropylene glycols, cetyl alcohol, cetostearyl alcohol, aryl alkyl polyether alcohols, polyoxyethylene-polyoxypropylene copolymers, poloxamines, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose, noncrystalline cellulose, polysaccharides, starch, starch derivatives, hydroxyethylstarch, polyvinyl alcohol, and polyvinylpyrrolidone.
44 . The composition of claim 37 , wherein the surface active biological modifier is selected from the group consisting of proteins, polysaccharides, and combinations thereof.
45 . The composition of claim 44 , wherein the polysaccharide is selected from the group consisting of starches, heparin and chitosans.
46 . The composition of claim 44 , wherein the protein is selected from the group consisting of albumin and casein.
47 . The composition of claim 36 , wherein the surface modifier comprises a copolymer of oxyethylene and oxypropylene.
48 . The composition of claim 47 , wherein the copolymer of oxyethylene and oxypropylene is a block copolymer.
49 . The composition of claim 36 , wherein the anticonvulsant agent is a tricyclic anticonvulsant agent.
50 . The composition of claim 49 , wherein the tricyclic anticonvulsant agent is carbamazepine.
51 . The composition of claim 36 , wherein the anticonvulsant agent is diazepam.
52 . The composition of claim 36 , wherein the anticonvulsant agent is clonazepam.
53 . The composition of claim 36 , wherein the anticonvulsant agent is lorezapam.
54 . The composition of claim 36 , wherein the anticonvulsant agent is a phenyltriazine.
55 . The composition of claim 54 , wherein the anticonvulsant agent is lamotrigine.
56 . The composition of claim 36 , wherein the anticonvulsant is the antidementia agent alprazolam.
57 . The composition of claim 36 , wherein the anticonvulsant is the antidementia agent risperidone.
58 . The composition of claim 36 , wherein the anticonvulsant is the antidementia agent sertraline.
59 . The composition of claim 36 , wherein the anticonvulsant is the antidementia agent zolpidem.
60 . The composition of claim 36 , wherein the anticonvulsant agent is phenytoin.
61 . A pharmaceutical composition of an immunosuppressive agent comprising solid particles of the agent coated with one or more surface modifiers, wherein the particles have an average effective particle size of less than about 50 nm to less than about 1000 nm.
62 . The composition of claim 61 , wherein the surface modifier is selected from the group consisting of: anionic surfactants, cationic surfactants, zwitterionic surfactants, nonionic surfactants, surface active biological modifiers, and combinations thereof.
63 . The composition of claim 62 , wherein the anionic surfactant is selected from the group consisting of: alkyl sulfonates, alkyl phosphates, triethanolamine stearate, sodium lauryl sulfate, sodium dodecylsulfate, alkyl polyoxyethylene sulfates, sodium alginate, dioctyl sodium sulfosuccinate, sodium carboxymethylcellulose, and calcium carboxymethylcellulose.
64 . The composition of claim 62 , wherein the cationic surfactant is selected from the group consisting of quaternary ammonium compounds, benzalkonium chloride, dimethylaminoethanecarbamoyl cholesterol, alkyl pyridinium halides, n-octylamine and oleylamine.
65 . The composition of claim 62 , wherein the anionic surfactant is a natural or synthetic phospholipid.
66 . The composition of claim 62 , wherein the cationic surfactant is a natural or synthetic phospholipid.
67 . The composition of claim 62 , wherein the zwitterionic surfactant is a phospholipid, and wherein the phospholipid is natural or synthetic.
68 . The composition of claim 62 , wherein the nonionic surfactant is selected from the group consisting of: polyoxyethylene fatty alcohol ethers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene fatty acid esters, sorbitan esters, glycerol monostearate, polyethylene glycols, polypropylene glycols, cetyl alcohol, cetostearyl alcohol, aryl alkyl polyether alcohols, polyoxyethylene-polyoxypropylene copolymers, poloxamines, methylcellulose, hydroxycellulose, hydroxy propylcellulose, hydroxy propylmethylcellulose, noncrystalline cellulose, polysaccharides, starch, starch derivatives, hydroxyethylstarch, polyvinyl alcohol, and polyvinylpyrrolidone.
69 . The composition of claim 62 , wherein the surface active biological modifier is selected from the group consisting of proteins, polysaccharides, and combinations thereof.
70 . The composition of claim 69 , wherein the polysaccharide is selected from the group consisting of starches, heparin and chitosans.
71 . The composition of claim 69 , wherein the protein is selected from the group consisting of albumin and casein.
72 . The composition of claim 61 , wherein the surface modifier comprises a copolymer of oxyethylene and oxypropylene.
73 . The composition of claim 72 , wherein the copolymer of oxyethylene and oxypropylene is a block copolymer.
74 . The composition of claim 61 , wherein the immunosuppressive agent is cyclosporin.
75 . The composition of claim 61 , wherein the immunosuppressive agent is beclomethasone.
76 . The composition of claim 61 , wherein the immunosuppressive agent is azathioprine.
77 . The composition of claim 61 , wherein the immunosuppressive agent is methylprednisolone.